Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Oncology to specialised palliative home care systematic transition: the Domus randomised trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. eHealth-mind the gap

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The burden of late effects among Hodgkin lymphoma (HL) survivors treated according to contemporary protocols remains poorly characterized. We used nation-wide registers to assess number of inpatient bed-days and specialist outpatient visits among 1048 HL-patients (<25 years, diagnosed 1990-2010) and 5175 country-, sex-, and age-matched comparators. We followed them for up to 24 years, with time-dependent assessment of relapse status. International Classification of Diseases (ICD-10) chapter-specific hazard ratios (HRs) were assessed in Cox regression analyses, and nonparametric statistics described patterns of health-care-use. Relative to comparators, relapse-free survivors were at increased risk of infections, diseases of the blood, endocrine, circulatory and respiratory systems, and unspecific symptoms, HRs ranging from 1.86 to 3.05. Relative to comparators, relapsed survivors had at statistically significantly increased risk of diseases reflecting practically all investigated disease-chapters, HRs ranging from 1.60 to 18.7. Among relapse-free survivors, 10% of the patients accounted for 80% of all hospital bed days, and 55% were never hospitalized during follow-up. Among relapsed-survivors, 10% of the patients accounted for 50% of the bed days, and only 24% were never hospitalized during follow-up. In contrast, 10% of the comparators accounted for 90% of hospital bed days and 75% were never hospitalized. These findings challenge the impression of a uniformly distributed long-term morbidity among all HL survivors and emphasize the need for early identification and attention to patients particularly susceptible to late effects, such as relapsed survivors.

OriginalsprogEngelsk
TidsskriftCancer Medicine
Vol/bind8
Udgave nummer10
Sider (fra-til)4918-4927
Antal sider10
ISSN2045-7634
DOI
StatusUdgivet - aug. 2019

Bibliografisk note

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

ID: 59260806